Cargando…

Treatment Patterns and Outcomes Among Patients With Advanced or Recurrent Endometrial Cancer Initiating First-Line Therapy in the United States

Background: Patients with advanced or recurrent endometrial cancer (EC) typically have limited treatment options and poor long-term survival outcomes following first-line therapy. Real-world treatment patterns and survival outcomes data are limited for patients in this setting. Objectives: The objec...

Descripción completa

Detalles Bibliográficos
Autores principales: Coleman, Robert L., Garside, Jamie, Hurteau, Jean, Nguyen, Joehl, Kobayashi, Monica
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Columbia Data Analytics, LLC 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10613433/
https://www.ncbi.nlm.nih.gov/pubmed/37905183
http://dx.doi.org/10.36469/001c.87853
_version_ 1785128832076873728
author Coleman, Robert L.
Garside, Jamie
Hurteau, Jean
Nguyen, Joehl
Kobayashi, Monica
author_facet Coleman, Robert L.
Garside, Jamie
Hurteau, Jean
Nguyen, Joehl
Kobayashi, Monica
author_sort Coleman, Robert L.
collection PubMed
description Background: Patients with advanced or recurrent endometrial cancer (EC) typically have limited treatment options and poor long-term survival outcomes following first-line therapy. Real-world treatment patterns and survival outcomes data are limited for patients in this setting. Objectives: The objective of this retrospective study was to describe real-world demographics, clinical characteristics, treatment patterns, and overall survival among patients in the United States with primary advanced or recurrent EC who initiated at least 1 line of therapy (LOT). Methods: Patients with a diagnosis of primary advanced or recurrent EC in a real-world database from January 1, 2013, to July 31, 2021, were included. The date for inclusion was the date of EC diagnosis documentation; patients were indexed for treatment patterns and outcomes at the start of the first LOT and at the start of each subsequent LOT they initiated. Data were stratified by subgroups of patients who had mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) tumors. Results: A total of 1961 patients who received at least 1 LOT were included. Most patients in this cohort, and the dMMR/MSI-H subgroup, received a platinum combination as first-line treatment, with carboplatin-paclitaxel being the most common regimen. Only 53% of patients who received first-line treatment subsequently received second-line therapy. Of the patients who received at least 1 LOT, use of immunotherapy in the second-line setting was more common in the dMMR/MSI-H subgroup. Median overall survival ranged from 14.1 to 31.8 months across the 5 most frequently used first-line treatment regimens in the ≥1 LOT cohort and became shorter with each subsequent LOT. Discussion: The use of platinum-based chemotherapy for first-line treatment of advanced or recurrent EC predominates in the real-world setting, despite the poor long-term survival outcomes associated with most of these regimens. Conclusions: Patients with recurrent/advanced EC have a poor prognosis, highlighting the need for therapies with more durable benefits.
format Online
Article
Text
id pubmed-10613433
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Columbia Data Analytics, LLC
record_format MEDLINE/PubMed
spelling pubmed-106134332023-10-30 Treatment Patterns and Outcomes Among Patients With Advanced or Recurrent Endometrial Cancer Initiating First-Line Therapy in the United States Coleman, Robert L. Garside, Jamie Hurteau, Jean Nguyen, Joehl Kobayashi, Monica J Health Econ Outcomes Res Oncology Background: Patients with advanced or recurrent endometrial cancer (EC) typically have limited treatment options and poor long-term survival outcomes following first-line therapy. Real-world treatment patterns and survival outcomes data are limited for patients in this setting. Objectives: The objective of this retrospective study was to describe real-world demographics, clinical characteristics, treatment patterns, and overall survival among patients in the United States with primary advanced or recurrent EC who initiated at least 1 line of therapy (LOT). Methods: Patients with a diagnosis of primary advanced or recurrent EC in a real-world database from January 1, 2013, to July 31, 2021, were included. The date for inclusion was the date of EC diagnosis documentation; patients were indexed for treatment patterns and outcomes at the start of the first LOT and at the start of each subsequent LOT they initiated. Data were stratified by subgroups of patients who had mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) tumors. Results: A total of 1961 patients who received at least 1 LOT were included. Most patients in this cohort, and the dMMR/MSI-H subgroup, received a platinum combination as first-line treatment, with carboplatin-paclitaxel being the most common regimen. Only 53% of patients who received first-line treatment subsequently received second-line therapy. Of the patients who received at least 1 LOT, use of immunotherapy in the second-line setting was more common in the dMMR/MSI-H subgroup. Median overall survival ranged from 14.1 to 31.8 months across the 5 most frequently used first-line treatment regimens in the ≥1 LOT cohort and became shorter with each subsequent LOT. Discussion: The use of platinum-based chemotherapy for first-line treatment of advanced or recurrent EC predominates in the real-world setting, despite the poor long-term survival outcomes associated with most of these regimens. Conclusions: Patients with recurrent/advanced EC have a poor prognosis, highlighting the need for therapies with more durable benefits. Columbia Data Analytics, LLC 2023-10-27 /pmc/articles/PMC10613433/ /pubmed/37905183 http://dx.doi.org/10.36469/001c.87853 Text en https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (4.0) (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Oncology
Coleman, Robert L.
Garside, Jamie
Hurteau, Jean
Nguyen, Joehl
Kobayashi, Monica
Treatment Patterns and Outcomes Among Patients With Advanced or Recurrent Endometrial Cancer Initiating First-Line Therapy in the United States
title Treatment Patterns and Outcomes Among Patients With Advanced or Recurrent Endometrial Cancer Initiating First-Line Therapy in the United States
title_full Treatment Patterns and Outcomes Among Patients With Advanced or Recurrent Endometrial Cancer Initiating First-Line Therapy in the United States
title_fullStr Treatment Patterns and Outcomes Among Patients With Advanced or Recurrent Endometrial Cancer Initiating First-Line Therapy in the United States
title_full_unstemmed Treatment Patterns and Outcomes Among Patients With Advanced or Recurrent Endometrial Cancer Initiating First-Line Therapy in the United States
title_short Treatment Patterns and Outcomes Among Patients With Advanced or Recurrent Endometrial Cancer Initiating First-Line Therapy in the United States
title_sort treatment patterns and outcomes among patients with advanced or recurrent endometrial cancer initiating first-line therapy in the united states
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10613433/
https://www.ncbi.nlm.nih.gov/pubmed/37905183
http://dx.doi.org/10.36469/001c.87853
work_keys_str_mv AT colemanrobertl treatmentpatternsandoutcomesamongpatientswithadvancedorrecurrentendometrialcancerinitiatingfirstlinetherapyintheunitedstates
AT garsidejamie treatmentpatternsandoutcomesamongpatientswithadvancedorrecurrentendometrialcancerinitiatingfirstlinetherapyintheunitedstates
AT hurteaujean treatmentpatternsandoutcomesamongpatientswithadvancedorrecurrentendometrialcancerinitiatingfirstlinetherapyintheunitedstates
AT nguyenjoehl treatmentpatternsandoutcomesamongpatientswithadvancedorrecurrentendometrialcancerinitiatingfirstlinetherapyintheunitedstates
AT kobayashimonica treatmentpatternsandoutcomesamongpatientswithadvancedorrecurrentendometrialcancerinitiatingfirstlinetherapyintheunitedstates